Cellegy Resubmits Cellegesic NDA For Anal Fissure Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA includes three pivotal trials for nitroglycerin ointment; the third trial was conducted under special protocol assessment after withdrawal of the original NDA in 2002. Cellegy has requested priority review.
You may also be interested in...
Cellegy Cellegesic Re-Analysis Of Anal Fissure Pain Relief Data Slated For Committee Review
FDA takes Cellegesic data analyses on pain reduction and fissure healing to cardio-renal advisory committee following protracted review.
Cellegy Cellegesic Re-Analysis Of Anal Fissure Pain Relief Data Slated For Committee Review
FDA takes Cellegesic data analyses on pain reduction and fissure healing to cardio-renal advisory committee following protracted review.
Cellegy Cellegesic Receives FDA “Not Approvable” Letter
Issues relate to pivotal studies for Cellegesic, even though the company conducted a third Phase III trial under a special protocol agreement with FDA. The letter “raised several issues that were not part of the agreed upon approval criteria,” Cellegy claims.